Novartis suffers setback as India revokes Entresto patent on evergreening grounds
The Indian Patent Office has revoked Novartis’ patent for its heart drug Vymada, or Entresto, citing “evergreening” and clearing the way for cheaper generics in a $2 billion market.In a major...To view the full article, register now.
Already a subscriber? Click here to view full article